Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy:: The LIFE study

被引:44
作者
Kjeldsen, SE
Dahlöf, B
Devereux, RB
Julius, S
de Faire, U
Fyhrquist, F
Ibsen, H
Kristianson, K
Lederballe-Pedersen, O
Lindholm, LH
Nieminen, MS
Omvik, P
Oparil, S
Wedel, H
机构
[1] Ullevaal Univ Hosp, Oslo, Norway
[2] Sahlgrens Univ Hosp, Gothenburg, Sweden
[3] Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA
[4] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Univ Helsinki, Cent Hosp, Helsinki, Finland
[7] Glostrup Univ Hosp, Glostrup, Denmark
[8] MRL Scandinavia, Stockholm, Sweden
[9] Viborg Hosp, Viborg, Denmark
[10] Umea Univ, Umea, Sweden
[11] Haukeland Hosp, N-5021 Bergen, Norway
[12] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA
[13] Nordic Sch Publ Hlth, Gothenburg, Sweden
关键词
atenolol; antihypertensive treatment; cardiovascular disease; electrocardiogram; left ventricular hypertrophy; losartan; randomized trial;
D O I
10.1016/S0895-7061(00)00280-6
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH). Baseline blood pressure was 174.4/97.8 mm Hg (mean), age 66.9 years, body mass index 28.0 kg/m(2): 54.1% were women and 12.5% had diabetes mellitus. This population will be treated until at least 1040 have a primary endpoint. After five scheduled visits and 12 months of follow-up, blood pressure decreased by 23.9/12.8 mm Hg to 150.5/85.1 mm Hg (target < 140/90 mm Hg). The mandatory titration level of less than or equal to 160/95 mm Hg was reached by 72.1% of the patients. At the 12-month visit, 22.7% of all patients were taking blinded study drug alone, 44.3% were taking blinded drug plus hydrochlorothiazide (HCTZ), and 17.7% were taking blinded drugs plus HCTZ and additional drugs. Controlling for all other variables, patients in the US received more medication and had 2.4 times the odds of achieving blood pressure control than patients in the rest of the study (P < .001). Previously untreated patients (n = 2530) had a larger initial decrease in blood pressure compared with those previously treated. Diabetics (n = 1148) needed more medication than nondiabetics to gain blood pressure control. Only 13.9% of the patients had discontinued blinded study drug and 1.4% missed the revisit at 12 months. These data demonstrate both the successful lowering of blood pressure during 12 months of follow-up in a large cohort of patients with hypertension and LVH on ECG, but also emphasize the need for two or more drugs to control high blood pressure in most of these patients. Being previously treated and having diabetes were associated with less blood pressure response, whereas living in the US indicated better blood pressure control. It has been possible to keep most of these patients with complicated hypertension taking blinded study drug for 12 months. (C) 2000 American Journal of Hypertension, Ltd.
引用
收藏
页码:899 / 906
页数:8
相关论文
共 10 条
  • [1] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS
    ANDERSON, KM
    WILSON, PWF
    ODELL, PM
    KANNEL, WB
    [J]. CIRCULATION, 1991, 83 (01) : 356 - 362
  • [2] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
  • [3] Chalmers J, 1999, J HYPERTENS, V17, P151
  • [4] Calcium-channel blockers for hypertension - Uncertainty continues
    Cutler, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (10) : 679 - 681
  • [5] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616
  • [6] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [7] JULIUS S, 1995, AM J HYPERTENS, V8, pA1
  • [8] MANAGEMENT GUIDELINES IN ESSENTIAL-HYPERTENSION - REPORT OF THE 2ND WORKING PARTY OF THE BRITISH-HYPERTENSION-SOCIETY
    SEVER, P
    BEEVERS, G
    BULPITT, C
    LEVER, A
    RAMSAY, L
    REID, J
    SWALES, J
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1993, 306 (6883): : 983 - 987
  • [9] Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
  • [10] Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
    Tuomilehto, J
    Rastenyte, D
    Birkenhäger, WH
    Thijs, L
    Antikainen, R
    Bulpitt, CJ
    Fletcher, AE
    Forette, F
    Goldhaber, A
    Palatini, P
    Sarti, C
    Fagard, R
    Staessen, JA
    Arabidze, GG
    Carrageta, M
    Celis, H
    Kocemba, J
    Leonetti, G
    Nachev, C
    O'Brien, ET
    Ritz, E
    Rodicio, JL
    Rosenfeld, J
    Heyrman, J
    Stibbe, G
    Van den Haute, H
    Yodfat, Y
    De Cort, P
    Hübner, GE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (09) : 677 - 684